BioWorld

Dec. 16, 2003

Velcade Performing Well In Confirmatory Phase III Trial

Millennium Pharmaceuticals Inc. stopped dosing the control arm of a confirmatory Phase III trial of Velcade, a cancer drug, after an independent review committee uncovered positive data in a prespecified interim analysis. (BioWorld Today) Read More

Trying Again: Idenix Files For Another Initial Public Offering

Juggling Anti-AIDS Drugs By Blasé Patients Spells Life-and-Death Risk As Tested In Massive Clinical Trial

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

Illustration of motor neuron connecting to muscle fiber

Research grants support early clinical trials of ALS treatments

BioWorld Science

The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...